+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
Prostate Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Prostate Cancer Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 188 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896567
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The prostate cancer therapeutics market is rapidly evolving, with continuous innovation in treatment methods and diagnostics requiring a renewed focus on operational agility and competitive differentiation for healthcare organizations, suppliers, and investors. Effective navigation of shifting regulatory frameworks and payer dynamics is critical for stakeholders aiming to optimize performance and maximize patient impact.

Market Snapshot: Prostate Cancer Therapeutics Market Growth and Outlook

The global prostate cancer therapeutics market grew from USD 11.21 billion in 2025 to USD 11.84 billion in 2026, with a projected CAGR of 6.64% and an expected value of USD 17.59 billion by 2032. This sustained growth is driven by ongoing advances in treatment modalities, the expanding use of precision-based care, and wider adoption of next-generation therapeutics within healthcare systems. Progressive integration of advanced diagnostics and heightened focus on evidence-based medicine are influencing both provider selection and payer reimbursement strategies. As real-time treatment monitoring becomes increasingly central, care teams and suppliers are reassessing competitive approaches and strategic options across international markets.

Scope & Segmentation of the Prostate Cancer Therapeutics Market

  • Therapeutic Mechanisms: Includes hormone-directed therapies, cytotoxic chemotherapy, radiopharmaceuticals, immunotherapies, and targeted agents. These leverage antiandrogens, CYP17 inhibitors, taxanes, monoclonal antibodies, PARP inhibitors, and checkpoint inhibitors to address a broad range of tumor profiles and resistance challenges.
  • Therapy Line Segmentation: Considers first-line, second-line, and third (or later) line therapies. This impacts treatment planning, tolerability assessments, and progression management for different patient subgroups.
  • Formulations: Covers injectable and oral delivery methods. Selection affects patient adherence, provider logistics, and the practical flow of care delivery within healthcare settings.
  • Distribution Channels: Encompasses hospital pharmacies, online pharmacies, and retail providers. Each distribution route influences patient access, inventory control, and fulfillment efficiency, especially for advanced therapies.
  • End-User Profiles: Represents cancer centers, specialty clinics, homecare organizations, and hospitals, each with distinct operational needs and resource requirements for treatment delivery.
  • Geographic Regions: Spans Americas, Europe, Middle East & Africa, and Asia-Pacific, with regional factors such as regulatory oversight, diagnostic infrastructure, and local manufacturing shaping adoption rates and supply chain performance.
  • Technologies: Features companion diagnostics, PSMA-targeted imaging, genomic profiling, and radioligand delivery. These solutions support precision targeting, real-time response tracking, and individualized therapy selection, underlining the growing role of technology-enabled personalization in therapeutic strategies.

Key Takeaways for Decision-Makers

  • Expanding portfolios of targeted and innovative therapies demand greater investment in clinical pathway design and companion diagnostic integration to address more nuanced patient requirements.
  • Ensuring supply chain resilience is increasingly vital due to the complex sourcing and sensitive logistics required for radiopharmaceuticals and biologics, which place pressure on infrastructure planning and operational risk strategies.
  • Partnering effectively with payers and health technology assessment agencies is crucial for market access; value-based arguments supported by real-world outcomes are now central to reimbursement success.
  • Strategic collaborations spanning clinical care, diagnostics, and distribution are accelerating commercialization trajectories, enabling faster and broader access for high-acuity treatments.
  • Robust segmentation by mechanism, therapy line, and care context allows tailored go-to-market and resource allocation strategies aligned to evolving market conditions and compliance requirements.
  • Differentiated regional approaches are necessary to manage regulatory divergence, diagnostic infrastructure variability, and supply chain contingencies, ensuring timely market entry and scalability.

Tariff Impact on Prostate Cancer Therapeutics Supply Chains

Current shifts in U.S. import tariffs and trade frameworks are placing upward pressure on sourcing costs for key ingredients, particularly radioligand precursors and biologic intermediates manufactured within global supply chains. In response, manufacturers are exploring onshoring, dual sourcing, and new supplier agreements to reduce exposure to disruption. Healthcare providers are emphasizing stable sourcing pathways to secure access to critical therapies, while escalating cost structures have sparked more intensive engagement with payers regarding value-based reimbursement models.

Methodology & Data Sources

This assessment is grounded in a triangulated research model, drawing from structured interviews with senior market experts, analysis of clinical and regulatory evidence, and multi-scenario outcome modeling. All findings have been validated through primary and secondary sources, such as major clinical trials, regulatory guidance, and market disclosures to ensure recommendations are actionable and credible.

Why This Report Matters

  • Enables senior leadership to pinpoint key operational opportunities and commercial risks by mapping current clinical, manufacturing, and market access dynamics.
  • Delivers actionable segmentation and targeted recommendations to support alignment of product development, supply chain models, and payer negotiation strategies.
  • Equips organizations to anticipate regulatory and logistical headwinds in priority regions, supporting proactive business planning and sustained patient access.

Conclusion

Realizing value in the prostate cancer therapeutics market requires cross-functional coordination in diagnostics, manufacturing, and stakeholder engagement. Organizations able to integrate new advances within robust operational structures are better positioned to enhance patient outcomes and long-term growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Prostate Cancer Therapeutics Market, by Therapeutic Mechanism
8.1. Chemotherapy
8.1.1. Platinum Compounds
8.1.2. Taxanes
8.2. Hormone Therapy
8.2.1. Antiandrogens
8.2.2. CYP17 Inhibitors
8.2.3. GnRH Agonists
8.2.4. GnRH Antagonists
8.3. Immunotherapy
8.3.1. Cancer Vaccines
8.3.2. Cell Therapy
8.3.3. Checkpoint Inhibitors
8.4. Radiopharmaceuticals
8.4.1. Alpha Emitters
8.4.2. Beta Emitters
8.5. Targeted Therapy
8.5.1. Monoclonal Antibodies
8.5.2. Parp Inhibitors
8.5.3. Tyrosine Kinase Inhibitors
9. Prostate Cancer Therapeutics Market, by Therapy Line
9.1. First Line
9.2. Second Line
9.3. Third Line And Beyond
10. Prostate Cancer Therapeutics Market, by Formulation
10.1. Injectable
10.2. Oral
11. Prostate Cancer Therapeutics Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Prostate Cancer Therapeutics Market, by End User
12.1. Cancer Centers
12.2. Homecare Providers
12.3. Hospitals
12.4. Specialty Clinics
13. Prostate Cancer Therapeutics Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Prostate Cancer Therapeutics Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Prostate Cancer Therapeutics Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Prostate Cancer Therapeutics Market
17. China Prostate Cancer Therapeutics Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Amgen Inc.
18.7. Astellas Pharma Inc.
18.8. AstraZeneca PLC
18.9. Bayer AG
18.10. Bristol-Myers Squibb Company
18.11. Celgene Corporation
18.12. Eisai Inc.
18.13. Eli Lilly and Company
18.14. F. Hoffmann-La Roche AG
18.15. Genentech, Inc.
18.16. GlaxoSmithKline plc
18.17. Ipsen S.A.
18.18. Janssen Pharmaceuticals, Inc.
18.19. Merck & Co., Inc.
18.20. Novartis AG
18.21. Pfizer Inc.
18.22. Sanofi S.A.
18.23. Takeda Pharmaceutical Company Limited
18.24. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 152. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 153. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 154. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 155. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 156. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 157. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 158. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 159. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 174. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 175. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 176. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 177. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 178. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 179. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 180. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 181. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 195. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 197. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 198. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 199. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 200. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 201. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 202. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 203. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 204. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 207. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 208. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 209. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 210. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 211. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 212. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 213. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 214. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 215. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 230. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 231. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 232. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 233. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 234. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 235. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 236. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 237. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 238. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 239. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 240. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 241. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 242. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 243. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 244. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 245. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 246. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 247. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 248. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 249. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 251. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 252. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 253. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 254. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 255. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 256. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 257. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 258. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 259. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 260. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 261. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 267. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 270. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 271. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 272. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 273. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 274. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
TABLE 275. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 276. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
TABLE 277. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 278. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
TABLE 279. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 280. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 281. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 282. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 283. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Prostate Cancer Therapeutics market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Ipsen S.A.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages188
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 11.84 Billion
Forecasted Market Value ( USD ) by 2032 $ 17.59 Billion
Compound Annual Growth Rate6.6%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Prostate Cancer Therapeutics - Global Strategic Business Report - Product Image

Prostate Cancer Therapeutics - Global Strategic Business Report

  • Report
  • 217 Pages
  • Global
From
Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Global Market Report 2025 - Product Image

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Prostate Cancer Therapeutics Market Report 2025 - Product Image

Prostate Cancer Therapeutics Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Castrate-Resistant Prostate Cancer Market Report and Forecast 2025-2034 - Product Image

Castrate-Resistant Prostate Cancer Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Prostate Cancer Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Prostate Cancer Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 110 Pages
  • Global
From

About the Prostate Cancer Drugs Market

The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy. The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.